Influence of pre-analytical and analytical factors on osteoprotegerin measurements

Clinical Biochemistry

Volumn 47, Issue 13-14, 2014, Pages 1279-1285

  Perez de Ciriza C ^a   Lawrie, A ^b   Varo, N ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Centrifugation; Interfering agents; OPG; Pre analytical variables; Serum

Indexed keywords

BILIRUBIN; BIOLOGICAL MARKER; CHOLESTEROL; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRIACYLGLYCEROL;

ADULT; BLOOD; CARDIOVASCULAR DISEASE; CHEMISTRY; FEMALE; HUMAN; MALE; PLASMA; SERUM;

ADULT; BILIRUBIN; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; HUMANS; MALE; OSTEOPROTEGERIN; PLASMA; RANK LIGAND; SERUM; TRIGLYCERIDES;

EID: 84929129917     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.05.006     Document Type: Article

References (32)

1. Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morinaga T., et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997, 234(1):137-142.
2. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89(2):309-319.
3. Venuraju S.M., Yerramasu A., Corder R., Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010, 55(19):2049-2061.
4. Boyce B.F., Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008, 473(2):139-146.
5. Baud'huin M., Duplomb L., Teletchea S., Lamoureux F., Ruiz-Velasco C., Maillasson M., et al. Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev 2013, 24(5):401-409.
6. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292(4):490-495.
7. D'Amelio P., Isaia G., Isaia G.C. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. J Endocrinol Invest 2009, 32(4 Suppl.):6-9.
8. Nybo M., Rasmussen L.M. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008, 159(5):603-608.
9. Malliga D.E., Wagner D., Fahrleitner-Pammer A. The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review. Wien Med Wochenschr 2011, 161(23-24):565-570.
10. Van Campenhout A., Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009, 204(2):321-329.
11. Caidahl K., Ueland T., Aukrust P. Osteoprotegerin: a biomarker with many faces. Arterioscler Thromb Vasc Biol 2010, 30(9):1684-1686.
12. Lawrie A., Waterman E., Southwood M., Evans D., Suntharalingam J., Francis S., et al. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol 2008, 172(1):256-264.
13. Vik A., Mathiesen E.B., Brox J., Wilsgaard T., Njolstad I., Jorgensen L., et al. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study. J Thromb Haemost 2011, 9(4):638-644.
14. Hosbond S.E., Poulsen T.S., Diederichsen A.C., Nybo M., Rasmussen L.M., Mickley H. Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scand Cardiovasc J 2012, 46(4):203-211.
15. Lieb W., Gona P., Larson M.G., Massaro J.M., Lipinska I., Keaney J., et al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010, 30(9):1849-1854.
16. Mesquita M., Demulder A., Damry N., Melot C., Wittersheim E., Willems, et al. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin Chem Lab Med 2009, 47(3):339-346.
17. Semb A.G., Ueland T., Aukrust P., Wareham N.J., Luben R., Gullestad, et al. Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol 2009, 29(6):975-980.
18. Condliffe R., Pickworth J.A., Hopkinson K., Walker S.J., Hameed A.G., Suntharaligam J., et al. Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension. Pulm Circ 2012, 2(1):21-27.
19. Clancy P., Oliver L., Jayalath R., Buttner P., Golledge J. Assessment of a serum assay for quantification of abdominal aortic calcification. Arterioscler Thromb Vasc Biol 2006, 26(11):2574-2576.
20. Interference testing in clinical chemistry; approved guideline-second edition. CLSI document EP7-A2 2005, Clinical and Laboratory Standards Institute, [25, no 27].
21. Theoleyre S., Wittrant Y., Tat S.K., Fortun Y., Redini F., Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004, 15(6):457-475.
22. Augoulea A., Vrachnis N., Lambrinoudaki I., Dafopoulos K., Iliodromiti Z., Daniilidis A., et al. Osteoprotegerin as a marker of atherosclerosis in diabetic patients. Int J Endocrinol 2013, 182060:2013.
23. Chan B.Y., Buckley K.A., Durham B.H., Gallagher J.A., Fraser W.D. Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. Clin Chem 2003, 49(12):2083-2085.
24. Trofimov S., Pantsulaia I., Kobyliansky E., Livshits G. Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population. Eur J Endocrinol 2004, 150(3):305-311.
25. Sennels H.P., Jacobsen S., Jensen T., Hansen M.S., Ostergaard M., Nielsen H.J., et al. Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. Scand J Clin Lab Invest 2007, 67(8):821-835.
26. Lippi G., Chance J.J., Church S., Dazzi P., Fontana R., Giavarina D., et al. Preanalytical quality improvement: from dream to reality. Clin Chem Lab Med 2011, 49(7):1113-1126.
27. Ueland T., Brixen K., Mosekilde L., Flyvbjerg A., Bollerslev J. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. J Clin Endocrinol Metab 2003, 88(3):1014-1018.
28. Fraser C.G. Inherent biological variation and reference values. Clin Chem Lab Med 2004, 42(7):758-764.
29. Defining, stabling and verifying reference intervals in the clinical laboratory; approved guideline-third edition. CLSI document EP28 A3c 2010, Clinical and Laboratory Standards Institute.
30. Chollet M.E., Brouland J.P., Bal dit Sollier C., Bauduer F., Drouet L., Bellucci S. Evidence of a colocalisation of osteoprotegerin (OPG) with von Willebrand factor (VWF) in platelets and megakaryocytes alpha granules. Studies from normal and grey platelets. Br J Haematol 2010, 148(5):805-807.
31. Lippi G., Brocco G., Salvagno G.L., Montagnana M., Guidi G.C., Schmidt-Gayk H. Influence of the sample matrix on the stability of beta-CTX at room temperature for 24 and 48 hours. Clin Lab 2007, 53(7-8):455-459.
32. Lippi G., Fortunato A., Salvagno G.L., Montagnana M., Soffiati G., Guidi G.C. Influence of sample matrix and storage on BNP measurement on the Bayer Advia Centaur. J Clin Lab Anal 2007, 21(5):293-297.